NOVO, DRF-2725 (NN622), a PPAR alpha and gamma agonist.
HYDERABAD, India, Sept. 7 /PRNewswire/ -- Dr. Reddy's announced today that Novo Nordisk has established clinical proof of concept for its novel dual-acting insulin sensitiser, DRF-2725 (NN622), and that Novo Nordisk has decided to initiate Phase 3 studies, which are expected to start later this year. Meanwhile, data from the Phase 2 studies will be presented for review to Novartis Pharma AG with which Novo Nordisk has partnered to commercialise DRF-2725 in North America.
Mads Krogsgaard Thomsen, chief science officer, Novo Nordisk, said: "We are very content with the results from the Phase 2 studies which support the dual-action profile of DRF-2725 (NN622), specifically targeting glucose control and dyslipidaemia in Type 2 diabetes. The results confirm a beneficial efficacy/safety profile allowing Novo Nordisk to select doses with a positive benefit/risk ratio for further development."
DRF-2725 (NN622) is a PPAR (peroxisome proliferator-activated receptor) alpha and gamma agonist, which in preclinical, early clinical and now also in Phase 2 trials has shown potential to regulate blood glucose and diabetic dyslipidaemia. The compound, out-licensed by Dr Reddy's Laboratories to Novo Nordisk, is chemically and pharmacologically different from presently marketed PPAR agonists.
Increasing scientific evidence within Type 2 diabetes indicates that targeting both elevated blood sugar levels and high lipid levels may improve treatment outcomes for these patients. Elevated blood sugar levels are typically measured as HbA1c, fasting plasma glucose and insulin, whereas high lipid levels for Type 2 diabetes patients are often manifested as too high triglyceride and free fatty acids levels and too low HDL-cholesterol. The compound is expected to be among the first to reach the market from a new generation of dual-acting sensitisers currently in development.
snip |
